Medtronic Gets FDA OK for Inceptiv Closed-Loop Spinal Cord Stimulator
By Colin Kellaher
Medtronic has won Food and Drug Administration approval of its Inceptiv closed-loop rechargeable spinal cord stimulator, or SCS, to treat chronic pain.
Medtronic on Friday said Inceptiv is its first SCS device to offer a closed-loop feature that senses biological signals along the spinal cord and automatically adjusts stimulation in real time.
The Dublin-based company said Inceptiv adjusts for movements such as laughing, bending or sneezing that can result in brief moments of uncomfortable overstimulation from traditional fixed-output SCS devices, which in turn may lead some patients to turn down their device's stimulation output.
Medtronic plans to initiate the U.S. market launch of Inceptiv, which was previously approved for sale in Europe and Japan, in the coming weeks.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 26, 2024 08:56 ET (12:56 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing
-
Going Into Earnings, Is Nvidia Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Arista Stock a Buy, a Sell, or Fairly Valued?
-
A Cheap Dividend Aristocrat to Buy Before It Bounces Back